File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients

TitleTherapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients
Authors
Yao, XZheng, BZhou, JXu, DZZhao, KSun, SHYuan, ZHWen, YM
KeywordsChronic hepatitis B
Cytokines
Dendritic cells
HBsAg-anti-HBs
Issue Date2007
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2007, v. 25 n. 10, p. 1771-1779 How to Cite?
DOI: http://dx.doi.org/10.1016/j.vaccine.2006.11.019
AbstractTo study the responses of chronic hepatitis B patients to yeast-derived HBsAg-HBIG complexes (YIC) and the mechanisms involved, twenty HBeAg-positive chronic hepatitis B patients were immunized with 60 μg of YIC or alum as the control at 4-week intervals, for 24 weeks. Five of ten patients responded to 60 μg YIC immunization showing ≥2 logs decrease of serum HBV DNA with loss or marked reduction of HBeAg and appearance of anti-HBe; two of these patients developed anti-HBs. Flares of alanine aminotransferase were observed in 4 of the 5 responders, and in 2 out of 10 control patients. HBsAg-stimulated peripheral blood mononuclear cells (PBMCs) secreted Th1/Th2 cytokines around 24 weeks after immunization. Dendritic cells incubated with YIC showed the highest levels of IL-12 secretion and up-regulation of functional markers. Thus, the therapeutic effect of YIC is associated with cytolytic and non-cytolytic responses in patients. © 2006 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/157471
ISSN
0264-410X
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.342
ISI Accession Number ID
WOS:000244642700009
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorYao, Xen_US
dc.contributor.authorZheng, Ben_US
dc.contributor.authorZhou, Jen_US
dc.contributor.authorXu, DZen_US
dc.contributor.authorZhao, Ken_US
dc.contributor.authorSun, SHen_US
dc.contributor.authorYuan, ZHen_US
dc.contributor.authorWen, YMen_US
dc.date.accessioned2012-08-08T08:50:14Z-
dc.date.available2012-08-08T08:50:14Z-
dc.date.issued2007en_US
dc.identifier.citationVaccine, 2007, v. 25 n. 10, p. 1771-1779en_US
dc.identifier.issn0264-410Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/157471-
dc.description.abstractTo study the responses of chronic hepatitis B patients to yeast-derived HBsAg-HBIG complexes (YIC) and the mechanisms involved, twenty HBeAg-positive chronic hepatitis B patients were immunized with 60 μg of YIC or alum as the control at 4-week intervals, for 24 weeks. Five of ten patients responded to 60 μg YIC immunization showing ≥2 logs decrease of serum HBV DNA with loss or marked reduction of HBeAg and appearance of anti-HBe; two of these patients developed anti-HBs. Flares of alanine aminotransferase were observed in 4 of the 5 responders, and in 2 out of 10 control patients. HBsAg-stimulated peripheral blood mononuclear cells (PBMCs) secreted Th1/Th2 cytokines around 24 weeks after immunization. Dendritic cells incubated with YIC showed the highest levels of IL-12 secretion and up-regulation of functional markers. Thus, the therapeutic effect of YIC is associated with cytolytic and non-cytolytic responses in patients. © 2006 Elsevier Ltd. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_US
dc.relation.ispartofVaccineen_US
dc.subjectChronic hepatitis B-
dc.subjectCytokines-
dc.subjectDendritic cells-
dc.subjectHBsAg-anti-HBs-
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAlanine Transaminase - Blooden_US
dc.subject.meshAntigen-Antibody Complex - Immunology - Therapeutic Useen_US
dc.subject.meshCytokines - Biosynthesisen_US
dc.subject.meshDna, Viral - Blooden_US
dc.subject.meshDendritic Cells - Immunologyen_US
dc.subject.meshHepatitis B Antibodies - Blood - Immunologyen_US
dc.subject.meshHepatitis B Surface Antigens - Immunologyen_US
dc.subject.meshHepatitis B E Antigens - Blooden_US
dc.subject.meshHepatitis B, Chronic - Immunology - Therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshLeukocytes, Mononuclear - Immunologyen_US
dc.subject.meshMiddle Ageden_US
dc.titleTherapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patientsen_US
dc.typeArticleen_US
dc.identifier.emailZheng, B:bzheng@hkucc.hku.hken_US
dc.identifier.authorityZheng, B=rp00353en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.vaccine.2006.11.019en_US
dc.identifier.pmid17224217-
dc.identifier.scopuseid_2-s2.0-33846650945en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33846650945&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume25en_US
dc.identifier.issue10en_US
dc.identifier.spage1771en_US
dc.identifier.epage1779en_US
dc.identifier.isiWOS:000244642700009-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridYao, X=34973484500en_US
dc.identifier.scopusauthoridZheng, B=7201780588en_US
dc.identifier.scopusauthoridZhou, J=7405550773en_US
dc.identifier.scopusauthoridXu, DZ=7404074134en_US
dc.identifier.scopusauthoridZhao, K=36574545200en_US
dc.identifier.scopusauthoridSun, SH=7404509430en_US
dc.identifier.scopusauthoridYuan, ZH=7401476740en_US
dc.identifier.scopusauthoridWen, YM=7401776949en_US
dc.identifier.issnl0264-410X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats